U.S. markets open in 22 minutes
  • S&P Futures

    4,068.75
    +10.00 (+0.25%)
     
  • Dow Futures

    33,497.00
    -11.00 (-0.03%)
     
  • Nasdaq Futures

    13,088.75
    +90.25 (+0.69%)
     
  • Russell 2000 Futures

    2,142.80
    +11.30 (+0.53%)
     
  • Crude Oil

    64.57
    -1.51 (-2.29%)
     
  • Gold

    1,817.00
    -5.80 (-0.32%)
     
  • Silver

    26.99
    -0.25 (-0.93%)
     
  • EUR/USD

    1.2092
    +0.0016 (+0.13%)
     
  • 10-Yr Bond

    1.6880
    -0.0070 (-0.41%)
     
  • Vix

    25.25
    +3.41 (+15.61%)
     
  • GBP/USD

    1.4041
    -0.0017 (-0.12%)
     
  • USD/JPY

    109.5410
    -0.1190 (-0.11%)
     
  • BTC-USD

    50,309.77
    -6,021.34 (-10.69%)
     
  • CMC Crypto 200

    1,366.40
    -197.43 (-12.62%)
     
  • FTSE 100

    6,908.25
    -96.38 (-1.38%)
     
  • Nikkei 225

    27,448.01
    -699.50 (-2.49%)
     

Humacyte to Present at Oppenheimer 31st Annual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Humacyte, Inc.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

DURHAM, N.C., March 11, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, will present at the virtual Oppenheimer 31st Annual Healthcare Conference March 18, 2021, at 8:40 a.m. EDT.

On February 17, 2021, Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, and Humacyte announced the execution of a definitive business combination agreement along with a fully committed $175 million PIPE financing agreement.

The webcast will be available for replay for 30 days following the presentation and can be accessed at www.Humacyte.com and https://wsw.com/webcast/oppenheimer9/register.aspx?conf=oppenheimer9&page=huma&url=https://wsw.com/webcast/oppenheimer9/huma/2712391.

About Humacyte
Humacyte, Inc., is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Pre-clinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s HAVs were the first product to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation and received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

Humacyte Investor Contact:
Doug Blankenship
CFO, Humacyte
dblankenship@humacyte.com

Humacyte Media Contacts:
Juliana Blum
EVP, Commercial
blum@humacyte.com

Heather Anderson
handerson@6degreespr.com